Cue Biopharma, Inc. (CUE) Q2 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings and welcome to the QBioPharma Investor Update Call. At this time, all participants are in a listen-only mode. A question and answer session will follow the presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the conference over to Dan Passeri, QBioPharma's Chief Executive Officer. Thank you. You may begin. All right, thank you very much, and good afternoon, everyone. As a reminder, this presentation and discussion is being recorded and will be available on our website for the next 30 days. Also, please be aware that the slides accompanying today's update may be advanced directly by those listening in on the call, and we'll be notifying you as we proceed through the presentation. Joining me on today's call is Dr. Anish Suri. our President and Chief Scientific Officer, Dr. Matteo Levassetti, our Chief Medical Officer, and Carrie Ann Millar, our Chief Financial Officer. As shown on slide number two, this presentation and overview may contain some forward-looking statements, and any forward-looking statement made during this call represents the company's views only as of today, August 9th, 2023. On the next slide, which is slide number three, just outlines the agenda for today's call, and I'll begin with a brief summary followed by a niche. A niche will provide you with some background context pertaining to our approach and resulting developments regarding the Immunostat platform with a brief synopsis of associated competitive advantages pertaining to the observations from our ongoing clinical trials. Following the background provided by Anish, Matteo will then provide an update on observations from our ongoin...